Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504604 · ClinicalTrials.gov registry record · NA
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
A NA study of Cholangiocarcinoma and Rare Cancers, sponsored by TargetCancer Foundation.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04504604: Recruiting NA study of Cholangiocarcinoma and Rare Cancers, sponsored by TargetCancer Foundation.
NCT04504604 is a NA study of Cholangiocarcinoma and Rare Cancers that is actively recruiting participants, run by TargetCancer Foundation. The registered enrollment target is 400 participants, roughly in line with the 379-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504604, a NA study of Cholangiocarcinoma and Rare Cancers, is actively recruiting participants, sponsored by TargetCancer Foundation.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Primary Outcome
The primary feasibility endpoint is the percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB. Point estimates and confidence interval estimations will be calculated for percent of participants on matched treatments.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST FoundationOne CDx and FoundationOne Liquid CDx
Study Locations (1)
Massachusetts
- TargetCancer Foundation - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT04504604 shows while recruiting
NCT04504604 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 379-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target.
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne CDx and FoundationOne Liquid CDx is the first listed.
NCT04504604 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04504604 about?
NCT04504604 is a clinical study titled "TCF-001 TRACK (Target Rare Cancer Knowledge) Study". This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
What is the current status of trial NCT04504604?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2020-10-01. Estimated completion is 2025-12.
What conditions does trial NCT04504604 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Rare Cancers, Cancer of Unknown Primary Site.
What interventions are being tested in trial NCT04504604?
The interventions under investigation include: FoundationOne CDx and FoundationOne Liquid CDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04504604?
This trial is sponsored by TargetCancer Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04504604 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04504604's enrollment target sits among peer trials
400 11th of 60 higher than 49 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI